Neonatal Herpes Simplex Virus Infections: Where Are We Now?
Neonatal herpes simplex virus (HSV) infection continues to cause significant morbidity and mortality despite advances in diagnosis and treatment. Prior to antiviral therapy, 85% of patients with disseminated HSV disease and 50% of patients with central nervous system disease died within 1 year. The advent of antiviral therapy has dramatically improved the prognosis of neonatal HSV with initially vidarabine and subsequently acyclovir increasing the survival rate of infected neonates and improving long-term developmental outcomes. More recently, polymerase chain reaction has allowed earlier identification of HSV infection and provided a quantitative guide to treatment. Current advances in the treatment of neonatal HSV infections are looking toward the role of prolonged oral suppression therapy in reducing the incidence of recurrent disease. Of concern, however, are increasing reports of acyclovir-resistant HSV isolates in patients following prolonged therapy.
KeywordsHerpes Simplex Virus Central Nervous System Disease Herpes Simplex Virus Infection Herpes Simplex Virus Encephalitis Neonatal Herpes Simplex Virus
- 20.Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA et al. . Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1996;174(6):1162–7.PubMedGoogle Scholar
- 27.Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S et al. . Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991;324(7):450–4.CrossRefPubMedGoogle Scholar
- 28.Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M et al. Administration of oral acyclovir suppressive therapy following neonatal herpes simplex virus disease limited to the skin, eyes, and mouth: results of a Phase I/II tiral. Pediatr Infect Dis J. 1996;15:247–54.CrossRefPubMedGoogle Scholar